The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.
Ying Cheng
No relevant relationships to disclose
Yun Fan
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Yunpeng Liu
No relevant relationships to disclose
Jiwei Liu
No relevant relationships to disclose
Dong Wang
No relevant relationships to disclose
Yan Yu
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Helong Zhang
No relevant relationships to disclose
Jun Liang
No relevant relationships to disclose
Jianhua Shi
No relevant relationships to disclose
Lijun Sheng
No relevant relationships to disclose